GSK's bepirovirsen delivers Phase 3 functional cure data
GSK (LSE:GSK) published positive Phase 3 results for bepirovirsen, its investigational hepatitis B treatment, with the data pointing to functional cure rates materially ahead of existing standard-of-care therapies. Chief Scientific Officer Tony Wood described the outcome as offering "the possibility of significantly better functional cure rates than the current standard of care", a milestone the hepatitis B field has long sought. The shares traded at 1919.0p, down 1.06% on the session.
Nuformix advances IPF candidate with FDA orphan backing
Nuformix (AIM:NFX) published full-year results that outlined continued progress on its inhaled idiopathic pulmonary fibrosis programme, NXP002. The company confirmed that FDA orphan drug designation is actively supporting partnering conversations, with management describing the inhaled IPF approach as "a viable and attractive concept," Chief Executive Dr Dan Gooding noted that external discussions are validating the pipeline's direction. The shares were quoted at 0.17p.
BSF Enterprise lists lab-grown T-rex leather bag at €500,000
BSF Enterprise (AIM:BSFA) announced that its Lab-Grown Leather subsidiary has secured a listing for its bio-engineered T-rex leather handbag in the catalogue of Paris auction house Hôtel Drouot, carrying an official price estimate of €500,000. The placement positions the product at the intersection of luxury goods and biotechnology, and drew significant market attention, lifting the shares 13.14% to 1.98p.
Physiomics builds translational framework for hantavirus drug development
Physiomics (AIM:PYC) disclosed the development of a hantavirus translational modelling workflow, linking in vitro antiviral screening data to human pharmacokinetic and pharmacodynamic modelling alongside virtual population simulations. The framework is designed to assess whether antiviral activity observed in the laboratory could translate into meaningful viral suppression in clinical settings, a capability that positions the company as a potential partner for infectious disease drug developers. The shares fell 7.14% to 0.65p.
SkinBioTherapeutics concludes board investigation, appoints new auditor
SkinBioTherapeutics (AIM:SBTX) confirmed that its board has completed its internal investigation, without disclosing further detail on the scope or findings at this stage. The company also announced the appointment of Saffrey as its new auditor, with further details expected shortly. The shares fell 4.88% to 9.75p as investors awaited additional clarity on the outcome.
Property Franchise Group flags regulatory tailwinds in trading update
Property Franchise Group (AIM:TPFG) issued a trading update confirming performance is running "in line with the Board's expectations," said Management pointed to regulatory-driven demand and recent deal activity as the key drivers of medium-term growth, offering reassurance to shareholders ahead of upcoming results. The shares edged down 0.26% to 476.255p.
